Fig. 7

Schematic picture of miR-494/G6pc axis involvement in metabolic plasticity of HCC cells and therapeutic potential of combined antimiR-494-based strategies. Metabolic alterations occurring in tumor cells are schematized in the central part of the picture. Circulating miR-494 levels in responder and non-responder HCC patients undergoing sorafenib treatment are presented in the right part of the picture. Treatment combinations with antimiR-494 (AM-494) are proposed for non-responder patients